关注
Helena Yu
Helena Yu
在 mskcc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
HA Yu, ME Arcila, N Rekhtman, CS Sima, MF Zakowski, W Pao, MG Kris, ...
Clinical cancer research 19 (8), 2240-2247, 2013
26232013
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ...
Cancer discovery 5 (8), 842-849, 2015
6162015
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
5822017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer
KC Arbour, E Jordan, HR Kim, J Dienstag, HA Yu, F Sanchez-Vega, P Lito, ...
Clinical Cancer Research 24 (2), 334-340, 2018
3972018
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
TK Sundaresan, LV Sequist, JV Heymach, GJ Riely, PA Jänne, WH Koch, ...
Clinical Cancer Research 22 (5), 1103-1110, 2016
3792016
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR …
AY Helena, CS Sima, J Huang, SB Solomon, A Rimner, P Paik, ...
Journal of Thoracic Oncology 8 (3), 346-351, 2013
3662013
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
N Marcoux, SN Gettinger, G O’Kane, KC Arbour, JW Neal, H Husain, ...
Journal of Clinical Oncology 37 (4), 278-285, 2019
3632019
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard, JCH Yang, H Yu, SW Kim, H Saka, L Horn, K Goto, Y Ohe, ...
Annals of Oncology 31 (4), 507-516, 2020
3502020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim …
LV Sequist, JY Han, MJ Ahn, BC Cho, H Yu, SW Kim, JCH Yang, JS Lee, ...
The Lancet Oncology 21 (3), 373-386, 2020
3492020
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Á Quintanal-Villalonga, JM Chan, HA Yu, D Pe’er, CL Sawyers, T Sen, ...
Nature reviews Clinical oncology 17 (6), 360-371, 2020
3372020
Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib
AJ Schoenfeld, KC Arbour, H Rizvi, AN Iqbal, SM Gadgeel, J Girshman, ...
Annals of Oncology 30 (5), 839-844, 2019
3212019
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega, BT Li, A Drilon, MG Kris, ...
Clinical Cancer Research 25 (3), 1063-1069, 2019
3072019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K Hastings, HA Yu, W Wei, F Sanchez-Vega, M DeVeaux, J Choi, H Rizvi, ...
Annals of Oncology 30 (8), 1311-1320, 2019
3002019
COVID-19 in patients with lung cancer
J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ...
Annals of Oncology 31 (10), 1386-1396, 2020
2982020
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
MJ Ahn, J Yang, H Yu, H Saka, S Ramalingam, K Goto, SW Kim, L Yang, ...
Journal of Thoracic Oncology 11 (4), S115, 2016
2882016
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
AJ Schoenfeld, JM Chan, D Kubota, H Sato, H Rizvi, Y Daneshbod, ...
Clinical Cancer Research 26 (11), 2654-2663, 2020
2772020
Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
M Offin, JM Chan, M Tenet, HA Rizvi, R Shen, GJ Riely, N Rekhtman, ...
Journal of Thoracic Oncology 14 (10), 1784-1793, 2019
2762019
Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain
AY Helena, SK Tian, AE Drilon, L Borsu, GJ Riely, ME Arcila, M Ladanyi
JAMA oncology 1 (7), 982-984, 2015
2492015
Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
HA Yu, K Suzawa, E Jordan, A Zehir, A Ni, R Kim, MG Kris, MD Hellmann, ...
Clinical Cancer Research 24 (13), 3108-3118, 2018
2292018
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
HA Yu, ME Arcila, MD Hellmann, MG Kris, M Ladanyi, GJ Riely
Annals of oncology 25 (2), 423-428, 2014
2132014
系统目前无法执行此操作,请稍后再试。
文章 1–20